Graham D. Thomas

Pfizer (United States) — United States

Immunology and Microbiology · Life Sciences

22h-index3.8kcitations37works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immune cells in cancer(20), Immune Cell Function and Interaction(9), Cancer Immunotherapy and Biomarkers(8), Immunotherapy and Immune Responses(5), Nuclear Receptors and Signaling(5)

Publications37 total

IL-12 and IL-18 can non-redundantly improve effector functions of in vitro-generated exhausted CD8+ T Cells 2389
The Journal of Immunology·2025Open Access
Therapeutic Blockade of Type 2 Cytokines and PD1 Unleashes Anti-Tumor Immunity Through Coordinated Reprogramming of Innate and Adaptive Immune Surveillance
2025Open Access
Nonclassical monocytes potentiate anti-tumoral CD8+ T cell responses in the lungs
Frontiers in Immunology·2023· 12 citedOpen Access
Reversing T-cell Exhaustion in Cancer: Lessons Learned from PD-1/PD-L1 Immune Checkpoint Blockade
Cancer Immunology Research·2021· 291 citedOpen Access
Combinatorial immunotherapy induces tumor-infiltrating CD8<sup>+</sup> T cells with distinct functional, migratory, and stem-like properties
Journal for ImmunoTherapy of Cancer·2021· 22 citedOpen Access
EZH2 Inhibition Compromises α4-1BB-Mediated Antitumor Efficacy by Reducing the Survival and Effector Programming of CD8+ T Cells
Frontiers in Immunology·2021· 2 citedOpen Access
Intra-Tumoral Activation of Endosomal TLR Pathways Reveals a Distinct Role for TLR3 Agonist Dependent Type-1 Interferons in Shaping the Tumor Immune Microenvironment
Frontiers in Oncology·2021· 16 citedOpen Access
CD8+ T Cell Exhaustion in Cancer
Frontiers in Immunology·2021· 471 citedOpen Access
CXCL9-expressing tumor-associated macrophages: new players in the fight against cancer
Journal for ImmunoTherapy of Cancer·2021· 118 citedOpen Access
EZH2 as a Regulator of CD8+ T Cell Fate and Function
Frontiers in Immunology·2020· 49 citedOpen Access
Baseline Frequency of Inflammatory Cxcl9-Expressing Tumor-Associated Macrophages Predicts Response to Avelumab Treatment
Cell Reports·2020· 79 citedOpen Access
Baseline Frequency of Inflammatory Cxcl9-Expressing Tumor-Associated Macrophages Predicts Response to Avelumab Treatment
Cell Reports·2020· 61 citedOpen Access
CD40 agonist-induced IL-12p40 potentiates hepatotoxicity
Journal for ImmunoTherapy of Cancer·2020· 22 citedOpen Access
Human Monocyte Heterogeneity as Revealed by High-Dimensional Mass Cytometry
Arteriosclerosis Thrombosis and Vascular Biology·2018· 176 cited
Scavenger Receptor CD36 Directs Nonclassical Monocyte Patrolling Along the Endothelium During Early Atherogenesis
Arteriosclerosis Thrombosis and Vascular Biology·2017· 82 citedOpen Access
Human Blood Monocyte Subsets
Arteriosclerosis Thrombosis and Vascular Biology·2017· 177 citedOpen Access
Diversity of Human Monocyte Subsets Revealed by CyTOF Mass Cytometry
The Journal of Immunology·2017· 4 cited
Abstract 1: Human Monocyte Diversity in Cardiovascular Disease Revealed by Mass Cytometry
Arteriosclerosis Thrombosis and Vascular Biology·2017
Deleting an Nr4a1 Super-Enhancer Subdomain Ablates Ly6C low Monocytes while Preserving Macrophage Gene Function
Immunity·2016· 163 citedOpen Access
2014 Jeffrey M. Hoeg Award Lecture
Arteriosclerosis Thrombosis and Vascular Biology·2016· 70 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Catherine C. Hedrick(14), Shahram Salek‐Ardakani(11), Paola Marcovecchio(6), Amy Blatchley(6), Wenjing Yang(6), Richard N. Hanna(5), Anouk A.J. Hamers(5), Heba Nowyhed(4), Rick M. Maizels(4), Judith E. Allen(4), Angela M. Taylor(4), Coleen A. McNamara(4), Purnima Sundar(4), Shobha Potluri(4), Peter C. Cook(4), Lucy H. Jackson‐Jones(4), Alexander Phythian‐Adams(4), Alasdair Ivens(4), Christopher J. Stairiker(4), Joseph S. Dolina(3)